Articles: function.
-
Pediatric Pulmonary Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Neonatal listeriosis, although rare, as incidence, leads to high mortality or outcome with sequelae among survivors. ⋯ Congenital listeriosis is an infection that may lead to severe injuries of almost all organs and may have a poor outcome despite early, proper treatment.Reference #1: Taege AJ. Listeriosis: recognizing it, treating it, preventing it. Cleve Clin J Med. Jun 1999;66(6):375-80DISCLOSURE: The following authors have nothing to disclose: Marta Simon, Manuela Cucerea, Zsuzsanna Gall, Monika Rusneac, Laura Suciu, Raluca Marian, Carmen MovileanuNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Exacerbations are the most frequent cause of hospitalization and death among patients with COPD. Combinations of long-acting bronchodilators maximize bronchodilation and may reduce the risk of exacerbations. QVA149, a once-daily dual bronchodilator containing the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium, improves lung function, breathlessness and rescue medication use compared with twice-daily salmeterol/fluticasone combination (SFC), in patients with moderate-to-severe COPD.1METHODS: In this 26-week, multicenter, double-blind study, patients ≥ 40 years with COPD (forced expiratory volume in 1 second [FEV1] ≥40% to <80% predicted and no history of exacerbations in the previous year) were randomized (1:1) to QVA149 110/50 µg or SFC 50/500 µg. In this post hoc analysis, we report the rate of mild, moderate or severe COPD exacerbations during 26 weeks of treatment with QVA149 or SFC. ⋯ Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Claus Vogelmeier: Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis, Pfizer, Almirall, Takeda, and Sterna Biologicals; has been paid lecture fees by AstraZeneca, Chiesi, GlaxoSmithKline, Janssen, Talecris, Novartis, Boehringer Ingelheim, Takeda, and Pfizer. Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Thoracic Surgery PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Surgery is the best treatment choice for most of pulmonary lesions. Pulmonary function tests (PFT) play an important role in this process by assessing the risks and the functional effects of the procedure. Our goal was to evaluate the impact of lung resection surgery on pulmonary function. ⋯ The following authors have nothing to disclose: Marta Sousa, Vitor Melo, Eloisa Silva, Jorge Vale, João Silva, Bárbara Rodrigues, António TorresNo Product/Research Disclosure Information.
-
Miscellaneous Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Hyperventilation refers to rapid or deep breathing and is commonly associated with panic and anxiety. Other common causes include somatisation, severe pain, infection, ketoacidosis, asthma, chronic obstructive pulmonary disease, pulmonary embolism and heart failure. ⋯ The following authors have nothing to disclose: Rui Ya Soh, Anne HsuNo Product/Research Disclosure Information.
-
Interstitial Lung Disease CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Hypersensitivity pneumonitis (HP) is characterized by diffuse inflammation of lung parenchyma. Symptoms include cough, fever, and shortness of breath. Chest imaging often shows micronodules and fibrosis that can be difficult to distinguish from idiopathic pulmonary fibrosis. We present a case of HP presenting with diffuse cystic lesions, mimicking lymphangioleiomyomatosis (LAM). ⋯ In patients with HP, treatment includes avoiding the allergen and in some cases, systemic corticosteroids. While long term prognosis is generally perceived as good, some patients develop severe respiratory insufficiency. We demonstrate the need to consider a HP diagnosis in patients with cystic lung disease.Reference #1: Ramazzini B. Diseases of workers. Wright WC, trans. New York, NY: Hafner, 1964; 243Reference #2: Cormier Y, et al Significance of pre- cipitins and asymptomatic lymphocytic alveolitis: a 20-yr follow-up. Eur Respir J. 2004;23(4):523-525.Reference #3: Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir CritCare Med. 1994;150(4):967-972DISCLOSURE: The following authors have nothing to disclose: Anita Rajagopal, Michael ShapiroNo Product/Research Disclosure Information.